AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Pictured: AbbVie Corporate Office/iStock, vzphotos

Drug Development

AbbVie’s Skyrizi Beats Remission Rates of J&J’s Stelara in Crohn’s Disease

In a follow-up readout, data from the head-to-head SEQUENCE study showed that AbbVie’s Skyrizi induced better rates of steroid-free remission in Crohn’s disease than Johnson & Johnson’s Stelara.

October 17, 2023

2 min read

Tristan Manalac

Pictured: American cash shaped into a funnel/iStoc

Deals

Early October Sees Torrid Pace of Biotech M&A—Will It Continue?

The first two weeks of October saw BMS’s $4.8 billion buyout of Mirati, Lilly’s $1.4 billion purchase of Point, Kyowa Kirin’s $387 million acquisition of Orchard and AbbVie’s $110 million Mitokinin deal.

October 13, 2023

2 min read

Greg Slabodkin

Pictured: Federal Trade Commission Sign/Courtesy o

Business

Pharma Companies Form Coalition to Fight FTC Antitrust Overhaul

AbbVie, Amgen, Gilead, Merck and Novartis are among the 31 members that have formed the Partnership for the U.S. Life Science Ecosystem to push back against federal antitrust reforms.

October 4, 2023

2 min read

Connor Lynch

Business

AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.

September 27, 2023

2 min read

Tristan Manalac

Update: AbbVie headquarters building in California

Business

AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products

After dropping an early-stage study more than a year ago, AbbVie has finally terminated its CD47 collaboration with I-Mab, leaving up to $1.3 billion in potential milestone payments on the table.

September 25, 2023

2 min read

Tristan Manalac

Pictured: Series of outcroppings with steep cliffs

Drug Development

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.

September 15, 2023

2 min read

Greg Slabodkin

Business

AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

September 14, 2023

2 min read

Tristan Manalac

Drug Development

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

September 13, 2023

2 min read

Tristan Manalac

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.

September 8, 2023

3 min read

Kate Goodwin

JOBS